胰高血糖素样肽-1对多囊卵巢综合征的影响被引量：3

Effects of glucagon-like peptide-1 on polycystic ovary syndrome

导出

摘要多囊卵巢综合征（PCOS）是女性最常见的内分泌紊乱疾病,发病率为6％～10％.发病机制主要包括胰岛素抵抗、高胰岛素血症、糖耐量减低、肥胖以及慢性炎性反应状态等.胰高血糖素样肽／鄄1（GLP-1）及其受体激动剂通过与GLP-1受体特异性结合而发挥作用,能够改善PCOS患者胰岛素抵抗、降低体重、降低炎性反应因子的表达等,增加患者受孕几率,因此在治疗PCOS中有着广阔的应用前景. Polycystic ovary syndrome （PCOS） is one of the most common endocrine disorders,with prevelane of 6%-10% in women.It has been demonstrated that PCOS is associated with insulin resistance,hyperinsulinemia,impaired glucose intolerance,obesity,and chronic inflammation,etc.Glucagon-like peptide-1 （GLP-1） and its receptor agonists act through specific combination of GLP-1 receptor,resulting in increased insulin sensitivity,weight loss and decreased expression of inflammatory factors.Therefore,it is helpful to increase infertility and useful to the treatment of PCOS.

作者曹琳郑仁东刘超

机构地区南京中医药大学附属江苏省中西医结合医院内分泌与代谢病院区

出处《国际内分泌代谢杂志》北大核心 2013年第6期389-391,共3页 International Journal of Endocrinology and Metabolism

关键词胰高血糖素样肽-1受体激动剂多囊卵巢综合征胰岛素抵抗炎症因子 Glucagon-like peptide-1 receptor agonist Polycystic ovary syndrome Insulin resistance Inflammatory factors

分类号 R711.75 [医药卫生—妇产科学]

引文网络
相关文献

参考文献17

1Tibaduiza EC, Chen C, Beinborn M. A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-ter- minal hormone binding domain. J Biol Chem,2001,276:37787-37793.
2Ehrmann DA. Polycystie ovary syndrome. N Engl J Med,2005,352: 1223-1236.
3Legro RS, Barnhart HX,Schlaff WD,et al.Clomiphene,met- formin, or both for infertility in the polyeystie ovary syndrome. N Engl J Med,2007,356:551-566.
4Parlevliet ET, de Leeuw van Weenen JE, Romijn JA, et al. GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet. Am J Physiol Endocrinol Metab,2010,299 :E318-E324.
5Wang L, Wu J, Cao H, et al.The correlation between intestinal gonadotropin-releasing hormone (GnRH)and proglueagon in hyperlipidemic rats and Goto-Kakizaki(GK)rats. Endoer pathol, 2009,20 : 227-234.
6Sancho V,Trigo MV,Gonzolez N,et al.Effects of glueagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats. J Mol Endocrinol.2005.35:27-38.
7Fan R, Kang Z, He L, et al. Exendin-4 improves blood glucose control in both young and aging normal non-diabetic mice, possible contribution of beta cell independent effects. PLoS One, 2011, 6: e20443.
8Ding X, Saxena NK, Lin S, et al. Exendin-4, a glucagon-like protein-1 (GLP-1)receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology,2006,43:173-181.
9Parlevliet ET, Schrnder-vander Elst JP, Corssmit EP, et al. CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice. J Pharmacol Exp Ther,2009,328:240-248.
10Natalicchio A, De Stefano F, Orlando MR, et al. Exendin-4 prevents c-Jun N-terminal protein kinase activation by tumor necrosis factor-st (TNF st) and inhibits TNF st-induced apop-tosis in insulin-secreting ceils. Endocrinology,2010,151:2019-2029.